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Lessons learned: new insights on the role of
cytokines in COVID-19
In the midst of resurging COVID-19 cases, the second NIH/FDA virtual COVID-19 and Cytokines symposium was held
on 1 December 2020, focusing on longitudinal studies of COVID-19 immunity, including long-term consequences,
potential associations with autoimmunity and the multisystem inflammatory syndrome in children (MIS-C).

A

central and ongoing quest in
COVID-19 research is to establish
why and how SARS-CoV-2
elicits heterogeneity in disease severity
and immunopathology among infected
individuals. Hence, much effort has been
exerted to understand the cellular basis of
SARS-CoV-2-induced immune responses,
with the aim of identifying new biomarkers
and prognostic tools and developing new
therapeutic options. Cytokines emerged
early as critical parameters in COVID-19
disease progression, and understanding
the qualitative, quantitative and temporal
differences in cytokine expression is
considered critical for the conquest
of COVID-19.
As the late-2020 fall surge brought the
third phase of the COVID-19 pandemic,
with record numbers of new cases and
deaths, the NIH/FDA Immunology,
COVID-19, and Cytokine Interest Groups
hosted the second NIH/FDA virtual
COVID-19 and Cytokines symposium,
bringing together experts in these areas
to present the most up-to-date data
and to provide a forum for discussion,
which focused on recent immunological
characterization of the disease and its
consequences, including MIS-C.
Opening with a summary of the current
challenges and achievements in fighting
SARS-CoV-2, Anthony Fauci (NIAID/NIH)
and Janet Woodcock (CDER/FDA)
presented a road map for extending these
efforts, as our understanding of the disease
and tools for managing COVID-19 are
evolving1. Fauci reflected on parallels with
the human immunodeficiency virus (HIV)
epidemic in the 1980s, which revealed gaps
in our knowledge but also led to many
outstanding basic and clinical discoveries.
Similarly, COVID-19 is an enormous
public health problem that challenges
scientists and clinicians to rapidly advance
our understanding of the immune system
and its impact on human disease. Fauci
further emphasized the importance of
delineating the role of cytokines in COVID19 pathogenesis and resolution and the
effects of antiviral and immunomodulatory
treatment strategies, as well as vaccines,
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on immune responses. In turn, Woodcock
pointed out that therapeutic interventions
serve as a learning tool and can provide new
insights into the pathogenesis of the disease.
However, the lack of markers defining
different stages of the disease has impeded
our understanding of the proper timing for
treatment regimens, with some therapies
resulting in negative effects when given too
late or too early in the disease course. The
work presented in this symposium outlined
efforts to address these issues.

Cellular origins of cytokines in
COVID-19

Adrian Hayday (Crick Institute and King’s
College) led the meeting by presenting
the results of a comprehensive analysis
of 63 patients with COVID-19 who were
segregated into three groups on the basis of
their disease severity. Patients were listed
as ‘low’ when mildly symptomatic (WHO
scores 1–2), ‘moderate’ when little or no
supplemental oxygen was required (WHO
scores 3–4) and ‘severe’ when they showed
any of the following indications: high-flow
oxygen requirement, mechanical ventilation,
multi-organ support or death (WHO scores
5–8). At the same time, 55 healthy adult
volunteers, of whom 23 had previously
experienced SARS-CoV-2 infection
without hospitalization, served as healthy
controls. Approximately 600 data points
were collected from an initial and then two
subsequent blood samplings, and these
data included complete serology, immune
cell analysis and, importantly, cytokine
expression (data are publicly available at
COVIDIP). Principal component analyses
of the datasets showed a clear segregation
of COVID-19 samples from control
samples, but no segregation of seropositive
and seronegative healthy controls2. Thus,
COVID-19 imposes a distinct immune
phenotype. A striking feature of immune
responses associated with severe COVID-19
turned out to be the loss of plasmacytoid
dendritic cells and basophils, which is
accompanied by extreme T cell cytopenia,
which mainly manifests as CD8+ T and
γδT cell depletion, even though T cells
are not targeted by SARS-CoV-2. Hayday

reminded us that isolated parameters rarely
provide immunological answers to viral
infections and that, in fact, the correlations
between the parameters provide more
insight about a given pathology. As such, it
was interesting that the expression of a triad
of cytokines, comprising interleukin (IL)-6,
IL-10 and interferon (IFN)-γ-induced
protein 10 (IP-10), is closely correlated
with disease progression. IP-10 (CXCL10)
is of particular interest because its
expression pattern in patients with
COVID-19 is distinct from that observed
with conventional viral infections. While
IP-10 is rapidly but transiently induced
in common cold viral infections, IP-10
concentrations frequently remain elevated
throughout the COVID-19 response.
Moreover, a decline in the level of serum
IFN-γ, a strong inducer of IP-10 expression,
did not affect IP-10 concentrations. These
findings suggest that IP-10 expression in
COVID-19 is maintained independently of
IFN-γ, albeit in a virus-dependent manner.
This distinct cytokine profile was confirmed
in an expanded study with 305 samples,
whereby the rise in cytokine production
correlated prognostically with deterioration
of patient health status. Notably, the
expression of IP-10, together with IL-6
and IL-10, was found to persist with
COVID-19 for over 72 hours after
admission. Elevated IP-10 was previously
reported for SARS-CoV and Middle
East respiratory syndrome coronavirus
(MERS-CoV) infections, so these features
may represent an immune signature of
severe coronavirus infection.
Identifying the distinct cytokine profile
and immune signature of COVID-19
has practical implications, as it can be
prognostic of clinical deterioration, such
as requiring intubation or mortality.
This led to the important question of
whether such distinct immune profiles
are only correlated with symptomatic
SARS-CoV-2 infection or whether they
are also associated with asymptomatic
individuals with SARS-CoV-2. To address
this question, Nina Le Bert (Duke-NUS
Medical School) studied a cohort of patients
in Singapore. Here, she asked whether the
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Fig. 1 | The family of disease states that fall under the umbrella term ‘cytokine storm’. The disease
phenotype of COVID-19 resembles that of other pathological syndromes that are driven by uncontrolled
immune system activation and cause cytokine storm. The consequent inflammation can lead to
tissue and organ damage. COVID-19 has overlap with features of acute respiratory distress syndrome
(ARDS) and post-viral syndromes. MIS-C has less lung involvement (ARDS) and more features of
Kawasaki disease. Assoc., association; CRS, cytokine release syndrome; EBV, Epstein–Barr virus; HLH,
hemophagocytic lymphohistiocytosis; Malig., malignancy; MAS, macrophage activation syndrome; SJIA,
systemic juvenile idiopathic arthritis.

T cell immune responses in symptomatic
versus asymptomatic COVID-19 differ
and whether disease severity would vary
depending on the quality of the immune
response. Importantly, COVID-19 cases
in Singapore represented a unique chance
to assess an understudied population, as
many patients are migrant workers, who
mostly reside in crowded dormitories.
Among the initial 541 recruits, 478 patients
underwent the initial assessment as well
as 2-week and 6-week follow-up exams.
This cohort was then divided on the basis
of COVID-19 symptoms: 44 individuals
were symptomatic, and the rest of the
individuals who tested positive (90.8%) were
asymptomatic. One of the first questions
was whether asymptomatic patients would
also mount productive immune responses to
SARS-CoV-2. The answer was a resounding
yes: anti-nucleoprotein IgG and neutralizing
antibody titers were comparable to those of
symptomatic patients. Titers also increased
with time (measured at 2 and 6 weeks after
the initial assessment), indicating a robust
humoral immune response regardless of
symptoms. To examine whether there
would be qualitative differences in the T cell
responses between the two groups, Le Bert
and colleagues utilized a pool of overlapping
peptides derived from the SARS-CoV-2
membrane (M), nucleoprotein (NP) and

spike (S) proteins and challenged T cells
from both symptomatic and asymptomatic
individuals. Both the strength and antigen
specificity of T cell responses showed
no major differences, indicating that the
magnitude of B or T cell reactivity did not
correlate with disease outcome. Next, whole
blood cells were stimulated with pools of
15-mer peptides from structural proteins of
SARS-CoV-2 and were assessed for cytokine
expression. The results demonstrated
that both symptomatic and asymptomatic
patients mounted strong cytokine responses
but that they segregated into distinct
clusters, wherein asymptomatic individuals
showed high expression of IL-2 and IFN-γ
while symptomatic individuals showed low
expression of IL-2 and IFN-γ. Collectively,
Le Bert’s data, as well as data from
Hayday, indicated that a combination of
parameters can segregate patients and
reflect their condition.
Another important but poorly
understood parameter is the contribution
of host factors to disease development
and progression. In this regard, Raphaela
Goldbach-Mansky (NIAID, NIH)
summarized her efforts to identify
the distinct immunological features of
SARS-CoV-2 infection in the context of the
host inflammatory response in patients with
severe disease. Whether the inflammatory
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responses in COVID-19 replicate those
in autoinflammatory diseases or whether
there are unique features in SARS-CoV-2
infection is not clear. In a joint effort
with Luigi Notarangelo and Helen Su
(both from NIAID), Goldbach-Mansky
analyzed a cohort of critically ill patients
from Northern Italy, focusing on changes
seen in inflammasomopathies and
interferonopathies. While autoinflammatory
diseases such as the macrophage
activation syndrome (MAS) or secondary
hemophagocytic lymphohistocytosis
(HLH) trigger ultra-high concentrations
of IL-18, COVID-19 elicited only modest
concentrations of this cytokine (Fig. 1).
Also, COVID-19 was rarely associated with
thrombocytopenia or hypertriglyceridemia,
which is distinct from what is observed
with MAS. Instead, patients with COVID19 displayed features of strongly activated
cytokine/chemokine secretion pathways
that are associated with NF-κB activation
and type II IFN expression. Conversely, the
antiviral pathway in COVID-19 appears
to be paralyzed, as demonstrated by weak
type I IFN responses. Thus, the loss of the
type I IFN response can be considered an
immune signature of COVID-19. In fact,
genetic variants affecting type I-IFNs3 or the
surprising presence of neutralizing type I
IFN autoantibodies4 correlate with disease
severity in some patients with COVID-19.
Along these lines, Alessandro Sette
(La Jolla Institute for Immunology) asked
whether there is pre-existing immunity
to SARS-CoV-2 in unexposed individuals
and, if so, how this could affect disease
progression. To understand the adaptive
immune response to SARS-CoV-2, Sette’s
group ventured to map the T cell epitopes in
convalescent patients with COVID-19 and
healthy unexposed controls5. Surprisingly,
SARS-CoV-2-reactive CD4+ T cells were
already present at significant frequencies
(~40–60%) in unexposed (obtained
before the emergence of SARS-CoV-2)
individuals. Epitope mapping further
revealed that these T cells (1) were mostly
reactive to non-spike proteins, (2) displayed
much greater responsiveness to peptides
from the homologous regions of the
common cold coronaviruses (CCC) than
to SARS-CoV-2 peptides and (3) were
mostly memory CD4+ T cells. Thus, these
results strongly suggested that there is
pre-existing immunity to SARS-CoV-2 in
healthy donors, which was acquired from
past infections with CCC. Whether such
cross-reactive antiviral immunity provides
protection against COVID-19 remains
to be examined. However, it is likely that
pre-existing T cell immunity would only
lessen the severity of the disease rather than
405
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prevent the infection itself. In support of
this hypothesis, T cell epitope mapping in
convalescent individuals revealed that the
repertoire significantly differed from that
in unexposed individuals. In-depth analysis
of T cell epitopes from 100 convalescent
individuals further identified a total of 280
major histocompatibility complex (MHC)
class II epitopes. These important data
revealed that the receptor-binding domain of
SARS-CoV-2 spike protein is a weak CD4+
T cell antigenic determinant and that 15–20
different epitopes are recognized by each
individual. For CD8+ T cells, a total of 523
MHC class I epitopes were identified, which
unveiled an interesting dichotomy between
the frequency and reactivity of the human
leukocyte antigen haplotype. As such, less
frequent HLA-A*0101-associated epitopes
showed a more vigorous response than
HLA-A*2601- and HLA-A*6801-associated
epitopes. Altogether, these results
documented a COVID-19-specific signature
in the T cell immune response that is
distinct from the response to CCC, and
epitope mapping further showed that HLA
binding is the main determinant of the
immunogenicity of SARS-CoV-2.

Multisystem inflammatory syndrome
in children

Despite initial optimism that children were
spared from the worst effects of COVID-19
(ref. 6), it soon became clear that children
could not only develop severe COVID-19
but also a rare secondary inflammatory
syndrome, now known as MIS-C. However,
the molecular basis of MIS-C and its
pathogenesis remain poorly understood.
Randy Cron (University of Alabama at
Birmingham) started the second session by
providing a comprehensive overview of the
history, clinical presentation and treatment
of this syndrome (Fig. 2). MIS-C was first
identified when the pandemic moved to
Europe and reports from Northern Italy7
and then the UK8 noted an approximately
30-fold increase in what was thought to be
Kawasaki disease (KD), an inflammatory
syndrome in children associated with fever,
rash, mucocutaneous inflammation and
vasculitis, particularly of cardiac arteries.
However, these patients were generally
more severely ill and had positive serology
for SARS-CoV-2, indicative of previous
infection or exposure and thus suggesting a
distinct entity. MIS-C has many overlapping
features with KD and toxic shock syndrome,
but patients are often older than those with
KD, which usually occurs in children under
the age of five. A similar post-COVID-19
inflammatory syndrome is also observed
in young adults but with more evidence
of carditis, including cardiac dysfunction,
406

shock and neurological involvement.
Notably, patients with MIS-C have more
pronounced lymphopenia, anemia and
thrombocytopenia as compared to patients
with KD. In addition to high C-reactive
protein (CRP) levels, troponins and
N-terminal pro-B-type natriuretic peptide
were specifically elevated, indicative of
cardiac involvement8. As the pandemic
spread to the US, reports of a similar disease
in New York and other states9,10 noted high
frequencies of gastrointestinal (GI) and
hematological features. The peak of MIS-C
in affected geographical regions generally
occurs a month or more after the peak
incidence of COVID-19 infections.
Cron proposed that KD is probably a
syndrome with multiple triggers (including
a previous infection with another
coronavirus) and proposed that MIS-C and
severe COVID-19 infection be included
under the umbrella of similar cytokine
storm syndromes (Fig. 1)11. He described
studies on the immunological effects of
MIS-C12,13, which included lymphopenia,
thrombocytopenia and elevated serum
IFN-γ, IL-1β, IL-6, IL-10 and IL-17
concentrations, although not to the same
extent as in the more severe cytokine storm
syndromes. Elevated concentrations of
IL-10 correlated with a lower viral load13,
and its presence together with elevated
concentrations of tumor necrosis factor
(TNF) was the best marker to distinguish
MIS-C from severe COVID-19. Notably,
unlike severe COVID-19, MIS-C is not
associated with pre-existing comorbidities,
with the occasional exception of asthma.
Cron outlined treatment options, which
included immunomodulatory agents
such as intravenous immunoglobulin
infusions, as used for KD, glucocorticoids,
anakinra (IL-1 receptor antagonist) and
infliximab (a monoclonal antibody to
TNF); antimicrobials, including remdesivir
and broad-spectrum antibiotics (as
some patients’ clinical pictures resemble
bacterially induced toxic shock syndrome);
and, in severe cases, mechanical ventilation,
pressor support and anticoagulants8,9,14,15.
Updated treatment guidelines were
published recently by the American College
of Rheumatology16.
To investigate MIS-C from a systems
biology perspective, similar to studying
COVID-19 in adults, Dusan Bogunovic
(Icahn School of Medicine at Mount Sinai)
described analyses of about 40 patients
treated at Mount Sinai in New York who
presented with the symptoms of MIS-C and
who met diagnostic criteria16. Treatment
with an IL-6R blocker and intravenous
immunoglobulin led to discharge, usually
within 5 days, with universally favorable

outcomes. To provide molecular insight
into the disease, they combined serology,
cytokine profiling, high-throughput
85-parameter immunophenotyping and
autoantibody analysis for nine of these
patients17. MIS-C SARS-CoV-2 antibody
responses resembled those seen in
convalescence, including effective virus
neutralization in vitro, but with lower IgM
and higher IgA concentrations. Multiplex
cytokine array data revealed a unique MIS-C
inflammatory cytokine signature not seen
in healthy controls or patients with COVID19, which included the expression of
chemokines (CXCL1, CXCL6 and CXCL11,
as well as CCL3 and CCL19) and cytokines
(including IL-6 and IL-17A, as noted by
Cron) involved in myeloid cell chemotaxis
and inflammation. In parallel, mass
cytometry immunophenotyping suggested
immune cell activation and egress of natural
killer (NK) and myeloid cells to peripheral
organs. Autoantibody analysis indicated the
presence of both autoantibodies targeting
organs central to MIS-C pathology,
including the GI tract, immune cells
and cardiac and epithelial tissue, and
some previously described autoantigens.
Interestingly, pathways involved in the
sensory detection of smell were also targeted
by autoantibodies. Using cellular indexing of
transcriptomes and epitopes by sequencing
(CITE–seq) to simultaneously detect surface
antigens and perform single-cell RNA
sequencing (scRNA-seq), Bogunovic and
his group found increased expression of
genes involved in lymphocyte activation and
cytotoxicity of NK and CD8+ T cells. These
findings were particularly pronounced in
a subset of patients who showed increased
phosphorylation of the signaling molecule
STAT3 across cell types.
To further address the molecular
mechanisms of MIS-C immunopathology,
Carrie Lucas (Yale School of Medicine)
focused on two potential causes of
post-COVID-19 MIS-C: (1) a rare second
hit with a pathogen within a certain window
of time after SARS-CoV-2 infection and (2)
a unique immune response to SARS-CoV-2
that triggers a transient reactivity against the
self. Lucas presented her team’s recent work
on a cohort of 15 patients who developed
MIS-C approximately 1 month after a peak
of COVID-19, whom they stratified into
two groups according to disease severity
(patients with severe disease were those
requiring ventilatory support or pressors)
(Fig. 2)18. She described CITE–seq results,
including T cell antigen receptor (TCR) and
B cell antigen receptor (BCR) repertoire
analyses, for peripheral blood mononuclear
cells from seven patients with MIS-C, as
well as from pediatric and adult patients
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Fig. 2 | Immunopathology associated with MIS-C post-SARS-CoV-2. MIS-C is characterized by fever and cardiovascular, GI tract, neurological, respiratory
and mucocutaneous inflammation. Immunological features include activation of both innate and adaptive responses, including elevated expression of genes
encoding S100 alarmins and increased concentrations of acute phase proteins (CRP, ferritin and D-dimers) as well as IL-6, IL-1β and CXCL10, indicative of
systemic inflammation. Activation of NK and CD8+ T cell cytotoxicity probably contributes to inflammation, as well as increased numbers of proliferating
plasmablasts, which may produce autoreactive IgGs. Endothelial damage is evidenced by elevated concentrations of soluble E-selectin in the serum and
cardiac damage by increased amounts of troponin and N-terminal pro-B-type natriuretic peptide (BNP). Figure adapted with permission from ref. 18, Cold
Spring Harbor Laboratory; made in ©BioRender—biorender.com.

with COVID-19 and controls. Evaluation
of transcriptional responses revealed that
antirespiratory virus and antibacterial
response signatures were low in patients
with MIS-C, confirming that SARS-CoV-2
infection was cleared, with no evidence
of secondary infection. Moreover, no
reads were present for Epstein–Barr
virus or cytomegalovirus. In parallel,
serum proteomics confirmed elevated
proinflammatory cytokines and chemokines
involved in myeloid cell infiltration into
the tissues, similar to the findings from
Bogunovic. Looking for the drivers of
this hyperinflammatory phenotype, they
analyzed gene expression in different cell
types and found that the expression of genes
encoding S100A alarmins was elevated
(similar to results in a recent report on

COVID-19 by Guo et al.19) and class II HLA
and CD86 were downregulated in myeloid
cells. Again, in NK cells and CD8+ T cells,
cytotoxicity genes (encoding perforin
and granzymes A and H) and IL-32 were
elevated (Fig. 2). Lucas also noted increased
numbers of plasmablasts in patients with
MIS-C, which were enriched for IgG1
or IgG3 isotypes and correlated with
proliferating CD4+ T cells with a B helper
gene profile. Patients with severe MIS-C
exhibited less TCR and BCR diversity,
elevated numbers of plasmablasts and
greater somatic hypermutation as compared
to the moderate disease group. The patients
with severe disease also exhibited elevated
concentrations of serum soluble E-selectin,
also seen in KD, suggesting endothelial
damage; functional experiments provided
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evidence for serum IgG antibodies
recognizing cultured endothelial cells.
Together with the work of Bogunovic,
these studies provide insight into
immunological signatures of MIS-C,
which, along with functional studies and a
potential mouse model, may help predict,
prevent and treat MIS-C post-SARS-CoV-2
infection in children. Nonetheless, many
questions remain, including whether
there is a specific trigger for MIS-C and
whether there are contributions from the
gut commensal microbiota or pathogens,
associations with food, or oral routes of
transmission, given the involvement of
the GI tract. Furthermore, although there
was no evidence of secondary respiratory
infection as a MIS-C trigger, tissue-specific
secondary infection or damage (such as
407
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from gut infections) or the involvement of
superantigens, a topic that was addressed in
the next talk, could not be ruled out.

Autoimmunity and other long-term
consequences of COVID-19

One of the most notable clinical outcomes
of SARS-CoV-2 is the induction of
autoimmune disease that persists long
after the resolution of acute viral infection
in a subpopulation of patients. This topic
was the focus of the talks from Alessio
Fasano (Massachusetts General Hospital),
Virginia Pascual (Weill Cornell Medicine)
and Leonard Calabrese (Cleveland Clinic),
who presented different aspects of the
intersection between COVID-19 and
autoimmunity. Fasano opened the session
by conveying data from several studies
performed in Italy suggesting that the
prevalence and severity of COVID-19
in patients with autoimmune diseases
(AIDs) is similar to those of the general
population20. However, symptoms consistent
with immune thrombocytopenic purpura
(ITP), Miller Fisher syndrome, Guillain–
Barré Syndrome (GBS), anti-phospholipid
syndromes (APLS) and MIS-C have
been described in patients following
SARS-CoV-2 infection, leading his group
to focus on the molecular mechanisms
that make the development of AIDs more
likely in patients with COVID-19 patients.
His talk centered on three principal
hypotheses21 underlying the induction of
autoimmunity by severe viral infection:
molecular mimicry, viral and bacterial
superantigens altering the T cell repertoire,
and lymphocyte apoptosis followed by
expansion of autoreactive lymphocytes.
Regarding molecular mimicry, he remarked
on multiple shared motifs between the
spike protein and human chaperone
proteins and hypothesized that altered
processing and presentation of endogenous
antigens could foster the recognition of
self-antigens. He also hypothesized that the
loss of tolerance associated with lymphocyte
apoptosis during acute infection followed
by a skewed expansion of the repertoire
could be involved, leading eventually to
autoimmunity, as proposed by Canas
et al22. However, Fasano considered the
strongest mechanistic trigger for the
hyperinflammatory syndrome and AID
induction to be viral superantigens within
SARS-CoV-2, which induce non-specific
activation and expansion of a distinct
population of T cells with a skewed TCR
repertoire, which leads to the expansion of
plasmablasts23. In particular, the expansion
of TCRBV11-2-bearing T cells appeared to
correlate with elevated proinflammatory
cytokines associated with cytokine storm
408

in children with MIS-C24. Lastly, drawing
from the parallels between MIS-C and
KD, Fasano described a potential role for
zonulin-dependent increased permeability
of the intestinal epithelial barrier and
proposed a provocative hypothesis wherein
the viral infection results in intestinal
dysbiosis (pertaining to altered gut
microbiota composition and function),
which then triggers MyD88-dependent
zonulin release. Once released, zonulin
binds to the proteinase-activated receptor 2,
triggering a sequence of signaling
events that ultimately cause disassembly
of tight junctional complexes and
increased GI mucosal permeability. This
increased mucosal permeability permits
viral or even bacterial antigens to be
internalized and act as superantigens,
thus triggering a cytokine storm and
autoimmunity (Fig. 3).
The autoimmune component of
COVID-19 was also explored by Pascual,
who described multiple studies indicating
parallels between COVID-19 and
autoimmune disorders. After describing
the clinical features shared by COVID-19
and AIDs, she focused on mechanistic
commonalities, particularly the central role
of type I IFNs. Citing findings published
by Casanova, Su and others regarding
the increased severity of COVID-19 in
patients with reduced IFN function due
to inborn errors in type I IFN immunity
or autoantibodies to type I IFNs3,4, she
emphasized the critical role of type I IFN
in controlling viral load. At the same
time, she remarked that the pattern of
IFN-inducible genes expressed following
a viral infection is similar to that in
systemic lupus erythematosus (SLE) and a
number of monogenic interferonopathies
described in children, as well as in subsets
of patients with other AIDs such as
Sjogren’s, dermatomyositis, thyroiditis and
diabetes, suggesting that it may underlie
some of the clinical features. Citing results
from Goldbach-Mansky and Notarangelo
that showed a 10-fold increase in type I
IFNs as well as an association between
CXCL10 and COVID-19 severity, Pascual
remarked that, although the expression of
interferon-inducible genes was lower in
patients with COVID-19 than in children
with interferonopathies or pediatric SLE,
it was in line with that observed in adults
with SLE25, leading her to emphasize the
different type I IFN responses in pediatric
and adult patients. In support of an
autoimmune component for COVID-19,
Pascual also remarked on the presence of
antibodies to IFNs, coagulation factors,
phospholipids and nucleic acids in patients
with COVID-19, which are characteristic of

several autoimmune disorders, signaling the
need to evaluate the long-term persistence
and potential sequelae of these antibodies
in patients that survive COVID-19.
Pascual, then focused on the emergence of
autoreactive T and B cells, again drawing
interesting parallels between the adaptive
immune responses in patients with COVID19 and pediatric patients with SLE. She
pointed to studies by Ignacio Sanz that
showed a potential role for the extrafollicular
activation of autoreactive B cells in patients
with severe COVID-19, drawing parallels
with SLE and underscoring a potential role
for a subpopulation of memory B cells that
lack follicular and conventional memory
markers but express Toll-like receptor 7
(TLR7) and antigen-presenting markers,
also seen in the peripheral blood of patients
with SLE26–28. She further proposed that the
surge in these extrafollicular plasmablasts
is possibly helped by extrafollicular
proinflammatory T cells displaying
exhaustion/hyperproliferative and cytotoxic
markers, as recently described for severe
COVID-19 (refs. 29,30). Interestingly, CD4+
T cells with similar characteristics that
lack follicular markers are also reported in
children with SLE, reinforcing the concept
that the dysfunctional immune response
in severe COVID-19 resembles that found
in SLE. Pascual then proposed a model
wherein virus-activated plasmacytoid
dendritic cells (pDCs) produce type I IFN
that primes CD4+ T cells to provide help
to extrafollicular B cells in unconventional
ways, as they do in SLE31. While the
cellular source of type I IFN has not been
confirmed, given the reported reduction
in blood pDCs in patients with COVID-19
(ref. 17) and SLE, she speculated that this
could correspond to increased migration
of pDCs to inflamed tissues32. Pascual’s talk
stressed that mechanistic understanding
of autoimmune diseases may help to
decipher the pathogenicity of COVID-19
and identify therapeutic targets. In turn,
detailed longitudinal studies of patients with
COVID-19 may shed light on pathogenic
autoimmune mechanisms and the potential
for immunomodulatory therapeutics to
mitigate autoimmune diseases.
The theme of shared mechanisms
between AIDs and COVID-19 was picked
up by Leonard Calabrese, who closed the
session by asking two questions: what can
we learn about cytokines in COVID-19 by
examining the outcomes for individuals with
pre-existing autoimmune/autoinflammatory
disorders who develop COVID-19, and what
effects do the commonly used therapies
for such autoimmune diseases, including
immune-pathway-targeted biologics
and non-biological disease-modifying
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Zonulin-dependent barrier
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spike influx

Normal/physiologically
controlled permeability

2)
SARS-CoV-2 in GI tract causes
dysbiosis and increased zonulin release
Mucus synthesis
and quality altered

Zonulin inhibitor
AT-1001

SARS-CoV-2 superantigen
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and cytokine storm
Superantigen-like
activity
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IFN-γ, IL-17, TNF

Hyperinflammation
associated with
severe COVID-19

Fig. 3 | Hypothesis on the pathogenesis of multisystem inflammatory syndrome in children and in adults (MIS-A). (1) Under physiological circumstances,
the homeostasis of the intestinal mucosa is maintained through tightly controlled antigen trafficking from the gut lumen into the lamina propria. (2) The
presence of SARS-CoV-2 (either as viable or non-viable viruses) in the GI tract causes dysbiosis and upregulates the expression of zonulin, a molecule that
controls paracellular permeability. (3) The zonulin-dependent increased gut permeability allows the paracellular passage of large, intact molecules, including
SARS-CoV-2-derived spike proteins, into the lamina propria. (4) Spike proteins, acting as superantigens, trigger T cell proliferation and cytokine storm, with
subsequent onsets of severe GI symptoms and systemic inflammation, which are typical of MIS-C and MIS-A. IVIG, intravenous immunoglobulin. SIgA,
secretory immunoglobulin A.

anti-rheumatic drugs (DMARDs), have on
the clinical outcome of COVID-19?
He consulted three patient registries to
attempt to answer these critical questions:
the COVID-19 Global Rheumatology
Alliance (GRA), consisting of the Global
UCSF Registry (3,572 patients) and the
European/EULAR registry (3,239 patients),
representing the largest database; the
Secure-IBD Database on COVID-19 (based
at the University of North Carolina at Chapel
Hill), a web-based voluntary reporting
system in which health care providers
report confirmed COVID-19 cases and
patient outcomes along with medication
exposure data; and the Psoriasis Registry for
Outcomes, Therapy and epidemiology of
COVID-19 infection (PsoProtect), containing
557 cases (at the time of reporting).
Calabrese pointed out that these
registries are imperfect for evaluating the
effects of underlying disease per se, as each
may impact COVID-19 prognosis, given
the markedly disparate and heterogeneous
diseases in these databases. However,
the effect of baseline therapies and risk
factors for severe disease or death were
still critically analyzed despite important
limitations regarding selection bias, low
granularity, lack of control comparators

and residual confounding factors in such
registries. He repeatedly emphasized that
such studies were important for hypothesis
generation rather than for producing
conclusive findings.
Initially reported at the American
College of Rheumatology meeting in
November 2020, data were also presented
at this meeting that examined risk factors
associated with death in the GRA database
from a population of over 4,000 patients.
Adjusting for multiple variables, the
following were associated with an increased
risk of death from COVID-19 (odds
ratio > 1): no DMARDs, sulfasalazine,
rituximab, and glucocorticoids at a dose
of >10mg per day. While rituximab’s
risk stems from the failure to generate
humoral immunity (and possibly T cell
immunity due to the lack of B cell antigen
presentation), and glucocorticoids at the
higher dose potently suppress antiviral
responses, the mechanism by which the
absence of DMARDs and sulfasalazine
contribute to enhanced risk is less clear. The
risk pertaining to glucocorticoids was also
identified in the SECURE-IBD database,
and a multivariate analysis (controlling
for age, sex, disease type, disease activity,
comorbidities, smoking, obesity, aspirin,
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and anti-TNF medication) revealed an
odds ratio of 6.87 for patients on higher
doses of steroids at the time of contracting
COVID-19. Similar results were found in
other IBD databases from Italy and the US.
Nonetheless, the need to understand the
context of glucocorticoid administration
was emphasized; while dexamethasone was
associated with poorer outcomes for patients
treated with higher doses of glucocorticoids
at the time of acquiring COVID-19 and
for patients with mild to moderate disease
(no oxygen required), it reduced deaths by
one third for patients receiving invasive
mechanical ventilation, and it is now the
standard of care (RECOVERY trial).
Calabrese then discussed the significance
of elevated inflammatory cytokines and the
effects of their blockade on the outcome of
COVID-19. He pointed to the importance
of TNF concentrations and downstream
IL-6 and IL-8 concentrations as directly
correlated with poor outcomes, including
hospitalization, transfer to an intensive care
unit, mechanical ventilation and death33,34.
He also emphasized the contribution
of TNF to diverse phenomena affecting
COVID-19, including neutrophil activation
and the release of neutrophil extracellular
traps (further inducing epithelial cell death),
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the loss of germinal centers and induction
of extrafollicular B cell responses, as well as
the generation of autoantibodies, including
phospholipid antibodies33. In this context,
he discussed analyses of the registries to
determine the effects of TNF blockers on
COVID-19. In both the GRA and PsoProtect
databases, treatment with TNF inhibitors
was associated with a favorable outcome,
with an odds ratio of 0.4 in the in the GRA
database (for hospitalization) and 0.60 in the
PsoProtect database (for intensive care unit
admission, need for mechanical ventilation,
and death). However, in the SECRURE-IBD
database, which employed a multivariate
analysis, TNF inhibition was associated with
a non-significant odds ratio of 0.9 for severe
outcomes. It is critical to note, however, that
the outcome was not worsened in patients
on TNF inhibitors and that such treatment
may potentially be beneficial.
The important topic of synergism
between cytokines in contributing to the
devastating hyperinflammation associated
with severe COVID-19 and whether
inhibition of multiple inflammatory
cytokines would improve the outcome
was discussed next. Citing work from
murine models, Calabrese discussed data
showing that TNF and IFN-γ can synergize
in mediating PANoptosis (pyroptosis,
apoptosis and necroptosis), associated with
the induction and perpetuation of cytokine
storm and cell death that is observed in both
sepsis and COVID-19 animal models35.
Moreover, treatment of murine cytokine
storm models, including SARS-CoV-2
infection, HLH and sepsis, with a
combination of TNF and IFN-γ inhibitors
markedly improved the outcome, suggesting
that dual blockade as compared to single
agents may improve outcomes in patients.
Blockade of IL-6 or IL-6R is known
to improve the outcome in patients with
cytokine release syndrome associated with
CAR-T cell therapy. However, although
serum IL-6 concentrations are correlated
with severe outcomes in COVID-19,
Calabrese noted that they are more similar
to IL-6 concentrations in acute respiratory
distress syndrome and sepsis and lower
than those in patients with cytokine release
in CAR-T cell therapy. Also noted were
the disappointing results thus far of IL-6
blockade in numerous randomized clinical
trials, several of which have been halted
due to futility. In the ACR database, the
only one in which IL-6 inhibitors are
tracked, patients with connective tissue
diseases appeared to have increased risk
of death from COVID-19 if treated with
IL-6 inhibitors. However, this was based
on a small number of patients, with a wide
confidence interval.
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Nonetheless, Calabrese echoed
Woodcock in questioning the timing
of IL-6 blockade administration as a
potential key to the lack of efficacy, citing
studies in which genetic polymorphisms in
the IL-6R gene that reduce IL-6 signaling
were shown to be salutary in COVID-19
as well as in cardiovascular disease. For
example, the Asp358Ala variant of the
IL-6R receptor disrupts IL-6 signaling and
is associated with reduced cardiovascular
disease frequency in the general population
and lower risk of both SARS-CoV-2
infection and hospitalization for COVID-19
(ref. 36). Calabrese concluded that
timing may indeed be a key issue in the
appropriate use of IL-6 inhibitors and
that treatment with such agents at the
onset of disease rather than later may have
beneficial effects.
The final topic was treatment of
COVID-19 with the JAK inhibitor
baricitinib. Noting that the ACTT-2 trial of
baricitinib and remdesivir versus remdesivir
alone had a favorable but very modestly
improved outcome for the combination
therapy (shortening of clinical disease by
only one day), Calabrese stressed that such
limited efficacy must be weighed against
the potential adverse consequences of
baricitinib, including inhibition of numerous
cytokines that may play an important role
in antiviral responses (type I IFNs, IL-12,
and so on), promotion of thromboembolism
(already a critical problem in patients with
COVID-19) and activation of endogenous
viruses, including herpes and BK viruses.
These potential negative effects must be
considered carefully against the marginally
improved outcome when baricitinib is
given in combination with remdesevir,
along with the antiviral properties that
have been identified for baricitinib37. Other
considerations regarding this agent include
issues of the timing of administration and,
critically, how its administration should be
considered in view of the known salutary
effects of dexamethasone for severe disease.
Finally, in addition to citing the utility
of registries for providing insights and
for hypothesis generation, Calabrese
concluded that the current data support
contextual roles for cytokines in disease
and their inhibitors in treatment, and these
are influenced by disease stage and the
associated immunologic ‘endotype.’ Such
considerations should be fundamental in
designing new trials. Importantly, all three
speakers agreed that the consensus at this
time is that infection with SARS-CoV-2
does not lead to flare-ups in patients with
AIDs. Of note, Calabrese remarked that
many patients had altered their treatment
following the onset of the pandemic,

complicating the assessment of the
consequences of the virus for these patients.

Concluding remarks

It has become abundantly clear that
cytokines play a commanding role in the
pathogenesis of COVID-19. Cytokine
expression is not only a prognostic
biomarker for the disease outcome and
severity of COVID-19, but SARS-CoV2-induced cytokine expression is also
understood to be a potent agitator of the
host immune system, leading to destructive
autoinflammation, organ failure and death.
As such, the second NIH/FDA symposium
on Cytokines in COVID-19 was timely,
showcasing cutting-edge research conducted
by the immunology community to
understand the cytokine-driven pathology
of COVID-19. Harnessing knowledge of the
virus as well as of autoimmune processes,
the speakers highlighted emerging areas
of research that may yield new therapeutic
targets to reduce the clinical impact of the
disease and minimize sequelae.
The virtual nature of the symposium
permitted speakers and audiences from
around the world to participate in real
time, with over 800 viewers logging in
on the day of the event and many more
subsequently making use of the archived
videos. Such worldwide interest illustrated
the cutting-edge nature of the talks but also
accentuated the need for rapid dissemination
of COVID-19-related data to the scientific
community. Nonetheless, it was also clear
that many questions remain, including the
expression patterns and timing of cytokines
that are relevant to the disease course and
how differences in genetics and environment
may contribute. Furthermore, the many
nuances to measuring cytokines, including
methods for and timing of the collection,
treatment, storage and assay of samples,
may need to be addressed before specific
cytokines can be used reproducibly as disease
biomarkers to monitor and predict disease
progression and recovery. SARS-CoV-2
presents a set of unique challenges that
require navigation through uncharted
territories and collaboration on the part of
the scientific community. We expect that
increasing efforts to interrogate the role of
cytokines in COVID-19 will provides us
with new tools to map and understand the
molecular landscape of this viral disease. ❐
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